<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00268411</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000453849</org_study_id>
    <secondary_id>GERCOR-D04-1-GEMOX</secondary_id>
    <secondary_id>EU-20569</secondary_id>
    <secondary_id>SANOFI-GERCOR-D04-1-GEMOX</secondary_id>
    <nct_id>NCT00268411</nct_id>
  </id_info>
  <brief_title>Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer</brief_title>
  <official_title>Phase II Randomisee Dans Les Adenocarcinomes Metastatiques Du Pancreas: Gemox Et Gemox Simplifie. [GEMOX]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It&#xD;
      is not yet known whether giving both of these drugs on the same day is more effective than&#xD;
      giving them on different days.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying two different schedules of gemcitabine&#xD;
      and oxaliplatin to compare how well they work in treating patients with metastatic pancreatic&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the objective response rate in patients with metastatic adenocarcinoma of the&#xD;
           pancreas treated with two different schedules of gemcitabine hydrochloride and&#xD;
           oxaliplatin.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the clinical benefits and tolerability of these regimens in these patients.&#xD;
&#xD;
        -  Compare the progression-free and overall survival of patients treated with these&#xD;
           regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to the&#xD;
      participating center and ECOG performance status (0 or 1 vs 2). Patients are randomized to 1&#xD;
      of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive gemcitabine hydrochloride IV over 100 minutes on day 1 and&#xD;
           oxaliplatin IV over 2 hours on day 2.&#xD;
&#xD;
        -  Arm II: Patients receive gemcitabine hydrochloride IV over 100 minutes followed by&#xD;
           oxaliplatin IV over 2 hours on day 1.&#xD;
&#xD;
      In both arms, treatment repeats every 14 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2004</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical benefits and tolerability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free and overall survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the pancreas&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
          -  Measurable disease (primary tumor or metastasis)&#xD;
&#xD;
               -  At least 1 cm in diameter by spiral CT scan&#xD;
&#xD;
          -  No ampulla of Vater carcinoma or biliary adenocarcinoma&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%&#xD;
&#xD;
          -  Life expectancy more than 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 5 times normal&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times normal&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times normal&#xD;
&#xD;
          -  No pre-existing neuropathy&#xD;
&#xD;
          -  No unstable or uncontrolled pain&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No serious cardiovascular disease&#xD;
&#xD;
          -  No serious respiratory disease&#xD;
&#xD;
          -  No uncontrolled or persistent hypercalcemia&#xD;
&#xD;
          -  No psychological, familial, social, or geographical condition that would preclude&#xD;
             study treatment&#xD;
&#xD;
          -  No other active malignancy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Louvet, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Saint Antoine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Duffaut</name>
      <address>
        <city>Avignon</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.G. Beauvais</name>
      <address>
        <city>Beauvais</city>
        <zip>60021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Drevon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Dreux</name>
      <address>
        <city>Dreux</city>
        <zip>28100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Departemental</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>F-85025</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint - Louis</name>
      <address>
        <city>La Rochelle</city>
        <zip>17000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Louis Pasteur - Le Coudray</name>
      <address>
        <city>Le Coudray</city>
        <zip>28630</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>F-72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique des Quatre Pavillons</name>
      <address>
        <city>Lormont</city>
        <zip>33310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Jean</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique De Courlancy</name>
      <address>
        <city>Reims</city>
        <zip>F-51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. Senlis</name>
      <address>
        <city>Senlis</city>
        <zip>60309</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>December 20, 2005</study_first_submitted>
  <study_first_submitted_qc>December 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2005</study_first_posted>
  <last_update_submitted>May 23, 2008</last_update_submitted>
  <last_update_submitted_qc>May 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2008</last_update_posted>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

